Cargando…

Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing

BACKGROUND: Ustekinumab (UST) is indicated for the treatment of Crohn’s disease (CD) and Ulcerative Colitis (UC). Despite having shown clinical effectiveness in the real world, some patients may lose response over time or need a higher dose to achieve it. In this context, UST intravenous (IV) mainte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Argüelles-Arias, Federico, Valdés Delgado, Teresa, Maldonado Pérez, Belén, González Antuña, Jaime, Castro Laria, Luisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467174/ https://www.ncbi.nlm.nih.gov/pubmed/37655058 http://dx.doi.org/10.1177/17562848231191670

Ejemplares similares

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2019)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease
por: Kakiuchi, Toshihiko, et al.
Publicado: (2021)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response
por: Heron, Valerie, et al.
Publicado: (2022)

Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study
por: Teresa, Valdés Delgado, et al.
Publicado: (2023)

Ustekinumab pharmacokinetics after subcutaneous administration in swine model
por: Grabowski, Tomasz, et al.
Publicado: (2021)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Refractory metastatic Crohn’s disease responsive to ustekinumab dose intensification
por: Xiao, Teresa L., et al.
Publicado: (2022)

Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis
por: Hu, Kelly A., et al.
Publicado: (2022)

Capsule Endoscopy in the Small Bowel Crohn's Disease
por: Argüelles-Arias, Federico, et al.
Publicado: (2014)

Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn’s disease
por: Yao, Jiayin, et al.
Publicado: (2023)

Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
por: Zhdanava, Maryia, et al.
Publicado: (2023)

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
por: Argüelles-Arias, Federico, et al.
Publicado: (2017)

The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab
por: Chiu, Hsien-Yi, et al.
Publicado: (2015)

On the Subcutaneous Injection of Blood, Infusion (Subcutaneous) and Intravenous Transfusion
por: Oehler,, et al.
Publicado: (1888)

Real-World Persistence, Maintenance Dosing, and Pre-Post Corticosteroid and Opioid Use Among Crohn’s Disease Patients with Prescription Claims for Ustekinumab in the USA
por: Ding, Zhijie, et al.
Publicado: (2021)

Comparison of the Mayo Endoscopy Score and the Ulcerative Colitis Endoscopy Index of Severity and the Ulcerative Colitis Colonoscopy Index of Severity
por: Belvis Jiménez, María, et al.
Publicado: (2021)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease
por: Haider, Syedreza A., et al.
Publicado: (2020)

A146 THE EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS
por: Albino, L, et al.
Publicado: (2022)

Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program
por: Yapa, S Wickramaratne Senarath, et al.
Publicado: (2016)

Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations
por: Leu, Jocelyn H., et al.
Publicado: (2022)

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
por: Abreu, Maria T, et al.
Publicado: (2022)

Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease
por: Roblin, Xavier, et al.
Publicado: (2023)

Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)

Late Reaction to Ustekinumab Infusion
por: Morais, Marina Resener, et al.
Publicado: (2013)

Efficacy and safety of ustekinumab in adolescents
por: Kellen, Roselyn, et al.
Publicado: (2016)

Ustekinumab-associated disseminated verrucae
por: Anderson, Mary E., et al.
Publicado: (2018)

Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohn’s Disease Patients: A Case Report and Review of the Literature
por: Thomas, Pepijn W A, et al.
Publicado: (2020)

Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model
por: Aguiar Zdovc, Jurij, et al.
Publicado: (2021)

Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
por: Delgado Sánchez, Olga, et al.
Publicado: (2019)

Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs
por: Werner, Ulrich, et al.
Publicado: (2020)

Case Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate–Severe Crohn’s Disease
por: Lee, Scott David, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn’s Disease
por: Dubinsky, Marla, et al.
Publicado: (2023)

Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009)

Ustekinumab for the treatment of psoriatic arthritis: an update
por: Davari, Parastoo, et al.
Publicado: (2014)

Bullous pemphigoid during ustekinumab therapy
por: Le Guern, Aurore, et al.
Publicado: (2015)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o06j2immn3uqhu0fpl3thfcdsg